Rafferty Asset Management, LLC Kodiak Sciences Inc. Transaction History

Rafferty Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.09 - $89.45 $452,008 - $5.7 Million	-63,753 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$80.85 - $128.49 $2.54 Million - $4.04 Million	31,429 Added 97.23%	63,753 $5.41 Million
Q3 2021 Nov 10, 2021	BUY	$81.97 - $106.94 $92,872 - $121,163	1,133 Added 3.63%	32,324 $3.1 Million
Q2 2021 Aug 10, 2021	BUY	$77.2 - $126.54 $382,217 - $626,499	4,951 Added 18.87%	31,191 $2.9 Million
Q1 2021 May 10, 2021	BUY	$110.45 - $164.47 $2.08 Million - $3.1 Million	18,830 Added 254.12%	26,240 $2.98 Million
Q4 2020 Feb 10, 2021	SELL	$60.78 - $154.03 $1.21 Million - $3.07 Million	-19,941 Reduced 72.91%	7,410 $1.09 Million
Q3 2020 Nov 13, 2020	BUY	$45.05 - $59.27 $701,203 - $922,537	15,565 Added 132.06%	27,351 $1.62 Million
Q2 2020 Aug 07, 2020	BUY	$42.74 - $66.25 $503,733 - $780,822	11,786 New	11,786 $638,000
Q1 2020 May 15, 2020	SELL	$38.18 - $73.95 $381,647 - $739,204	-9,996 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$13.9 - $76.65 $138,944 - $766,193	9,996 New	9,996 $719,000

109

40.9M

28.4K

21.2K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $171M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.